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Mitochondrial respiratory chain dysfunction is responsible for a large variety of early and late-onset diseases. NADH-ubiquinone
oxidoreductase (complex I) defects constitute the most commonly observed mitochondrial disorders. We have generated Caenorhabditis elegans
strains with mutations in the 51 kDa active site subunit of complex I. These strains exhibit decreased NADH-dependent respiration and lactic
acidosis, hallmark features of complex I deficiency. Surprisingly, the mutants display a significant decrease in the amount and activity of
cytochrome c oxidase (complex IV). The metabolic and reproductive fitness of the mutants is markedly improved by riboflavin. In this study, we
have examined how the assembly and activity of complexes I and IV are affected by riboflavin. Our results reveal that the mutations result in
variable steady-state levels of different complex I subunits and in a significant reduction in the amount of COXI subunit. Using native gel
electrophoresis, we detected assembly intermediates for both complexes I and IV. Riboflavin promotes the assembly of both complexes, resulting
in increased catalytic activities. We propose that one primary pathogenic mechanism of some complex I mutations is to destabilize complex IV.
Enhancing complex I assembly with riboflavin results in the added benefit of partially reversing the complex IV deficit.
© 2005 Elsevier B.V. All rights reserved.Keywords: Mitochondria; Complex I; Complex IV; C. elegans1. Introduction
The best-known function of mitochondria is to provide
cellular energy via the process of oxidative phosphorylation
(OXPHOS). OXPHOS is mediated by the mitochondrial
respiratory chain (MRC), which is composed of four mem-
brane-bound electron-transporting protein complexes (I–IV)
that generate a proton gradient across the mitochondrial inner
membrane and the ATP synthase (complex V) that utilizes the
proton gradient for ATP generation. Defects in one or more
MRC complex impair OXPHOS and can result in mild to severe
disease or even lethality. Deficiency in complex I, the NADH-
ubiquinone oxidoreductase, is the most prevalent form of MRC
disorder [1–4]. Mammalian complex I is the largest respiratory
chain complex, composed of at least 46 subunits, seven of
which are encoded in the mitochondrial DNA (mtDNA) [5,6]. A
flavin mononucleotide (FMN) co-factor serves as the entry
point for electrons from NADH oxidation, while up to eight⁎ Corresponding author. Tel.: +1 780 492 4853; fax: +1 780 492 0886.
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enzyme [7–10]. Electron transfer from NADH to ubiquinone is
coupled to vectorial proton movement across the inner
membrane [11]. Complex I dysfunction is linked to cardiomy-
opathies, encephalomyopathies and neurodegenerative disor-
ders such as Parkinson's disease and Leigh syndrome [3,4,12].
The exact pathophysiological mechanisms involved in most
mitochondrial diseases remain poorly understood. To better
describe the bioenergetic and biochemical consequences of
MRC dysfunction, we developed a Caenorhabditis elegans
model of complex I deficiency [13,14]. C. elegans complex I is
composed of at least 40 subunits, many of which share very
high sequence identity to their human homologues [15,16]. Our
nematode strains express missense mutations in the nuclear-
encoded nuo-1 gene, the nematode orthologue of the human
NDUFV1 gene [13]. The nuo-1 and the NDUFV1 genes encode
the 51-kDa subunit of complex I, which carries the NADH-
binding site, the FMN cofactor and an iron–sulfur cluster.
Patients with NDUFV1 mutations present with a myriad of
symptoms including hypotonia, myoclonic epilepsy, brain
atrophy, macrocystic leukodystrophy, acute metabolic acidosis
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expressing the A352V, T434M or the A443F amino-acid
substitutions in the NUO-1 protein. These mutants demonstrate
hallmark features of complex I dysfunction such as lactic
acidosis and decreased NADH-dependent respiration. In
addition, we noted specific catalytic deficiencies in complexes
I and IV, particularly in the more severe A352V and A443F
mutants [13].
A variety of pharmacological agents are used to treat
MRC dysfunction, although there is little solid evidence
supporting their use [20,21]. Riboflavin (vitamin B2)
produces significant increases in fertility in all three nuo-1
mutants [13]. Interestingly, riboflavin has previously been
associated with successful treatments for complex I defi-
ciency [22–25]. Riboflavin is a precursor to the flavin
cofactors FMN and FAD (flavin adenine dinucleotide),
which serve as coenzymes for numerous reactions involving
one and two-electron oxidation-reduction reactions. Complex
I utilizes FMN as the initial electron acceptor during the
oxidation of NADH. Another important riboflavin-dependent
metabolic reaction is catalyzed by the pyruvate dehydroge-
nase complex (PDHC), an FAD-containing enzyme that
oxidizes pyruvate and releases acetyl-coenzyme A. This
reaction is the major source of substrate for the Krebs cycle.
If PDHC activity is low, pyruvate generated by glycolysis
can accumulate and be converted to lactate, resulting in
lactic acidosis. Riboflavin supplementation of complex I-
deficient worms may also stimulate PDHC activity and the
Krebs cycle; this is consistent with the marked attenuation
of lactic acidosis we noted in the A443F mutant by
riboflavin [13].
Mutations leading to complex I deficiency may be localized
to either nuclear or mtDNA-encoded complex I genes or in
genes encoding proteins that mediate the assembly of subunits
and cofactors into the holoenzyme [26–29]. In contrast, clinical
deficiency of cytochrome c oxidase is almost never a result of
mutation in one of its structural subunits but rather is a result of
an assembly factor defect [30,31].
To better understand the molecular bases of pathogenic
complex I mutations, we have investigated the assembly and
catalytic function of complexes I and IV in C. elegans nuo-1
mutants. nuo-1 mutations are pathogenic because they desta-
bilize complex I and impair the assembly of complex IV. Here,
we also report that the assembly defects for both complexes I
and IV are riboflavin-responsive. Complex IV assembly defects
are indirectly corrected by riboflavin supplementation because
complex IV is not a flavoprotein.
2. Materials and methods
2.1. Strains
Worms were cultured as described [32]. We used the following C. elegans
strains: N2 (Bristol) wild type; LB25, nuo-1(ua1) II, unc-119(ed3) III, uaEx25
[p016bA352V]; LB26, nuo-1(ua1) II, unc-119(ed3) III, uaIs26
[p016bT434M]; LB27, nuo-1(ua1) II, unc-119(ed3) III, uaEx27
[p016bA443F] [13]. Worms cultured in liquid medium were supplemented
with 1 μg/ml riboflavin with additional riboflavin added every second day
until harvested.2.2. Electrophoresis and Western blot analyses
Mitochondria were isolated as previously described [13]. Fifty μg of
mitochondrial protein were solubilized in gel-loading buffer and resolved by
electrophoresis on 10% or 12% sodium dodecyl sulfate (SDS) polyacrylamide
gels [14]. Proteins were transferred electrophoretically to nitrocellulose or
polyvinylidene fluoride membranes. Blots were treated with rabbit polyclonal
antisera against the bovine 51-kDa subunit (a gift from Dr. M. Yamaguchi,
USA), the N. crassa TYKY subunit (a gift from Dr. F. Nargang, Canada) or the
Saccharomyces cerevisiaeATP-2p [33]. Another source of antiserum against the
51-kDa protein gave similar results, indicating the specificity of the bovine
serum. Mouse monoclonal antisera against the human NDUFS3 protein (30-kDa
complex I subunit) or COXI (MitoSciences, Eugene, Oregon) were also used.
For development, blots were treated with peroxidase-labeled goat anti-rabbit or
goat anti-mouse secondary antibodies. The Enhanced Chemiluminescence
Western Blotting System (Amersham Biosciences, Buckingham, UK) or the
Super Signal West Femto Maximum Sensitivity Substrate (Pierce Biotechnol-
ogy, Inc., Rockford, IL) were used for detection. Signal quantification was
performed with the BioRad Gel Doc 1000 Image Analysis System and
Molecular Analysts software (BioRad Laboratories, Hercules, CA).
2.3. Native gel electrophoresis and histochemical staining
Blue native gradient gels (4–13% for complex I analysis; 5–15% for
complex IV analysis) were loaded with 300 μg mitochondrial protein as
described [34]. Following electrophoresis, NADH dehydrogenase activity was
detected by incubating gels in 20 ml 50 mM Tris–HCl, pH 7.4 containing 0.5
mM tetranitroblue tetrazolium and 5 mM NADH at 37 °C for 80 min in the dark
with gentle rocking. For the detection of cytochrome c oxidase activity, gels
were incubated in 20 ml 50 mM Tris–HCl, pH 7.4 containing 0.1% 3,3′-
diaminobenzidine, 0.1% cytochrome c, 0.02% catalase at 37 °C for 90 min in the
dark with gentle rocking. Gels used for Western blot analysis were incubated in
20 mM Tris-base, 150 mM glycine, 20% (v/v) methanol, 0.08% (w/v) SDS for
10 min before electrophoretic transfer to Immobilon-P membranes (Millipore
Corp., Billerica, MA) [35]. Following transfer, excess stain was removed as
described [36].
2.4. MRC assays
Enzymatic activities were measured on an Ultrospec 2000 spectrophotom-
eter (Pharmacia Biotech, Cambridge, UK) as described [37]. Rotenone-sensitive
NADH-decylubiquinone oxidoreductase activity was measured at 340 nm using
65 μM 2,3-dimethoxy-5-methyl-6-n-decyl-1,4-benzoquinone as electron accep-
tor, 2 μg/ml antimycin A, 0.13 mM NADH. Rotenone was added to 2 μg/ml.
Cytochrome c oxidase activity was measured at 550 nm using 15 μM
cytochrome c as electron acceptor in the presence of 0.45 mM lauryl maltoside.
Potassium cyanide was added to 1 mM.
3. Results
3.1. Steady-state levels of complexes I and IV are reduced in
nuo-1 mutants
We investigated the steady state levels of complexes I and IV
in mitochondria isolated from wild type C. elegans and from
three complex I-deficient strains: LB25, LB26 and LB27. LB25
and LB27 carry extrachromosomal transgenic arrays expressing
the A352Vand A443F nuo-1 alleles, respectively. LB26 carries
an integrated transgene encoding the T434M nuo-1 mutation.
The relative abundance of three complex I subunits was
determined by Western blot analysis. We observed severe
reductions in the amounts of NUO-1 protein (51-kDa subunit),
moderate reductions in the amounts of 30-kDa subunit but no
reduction in the amounts of TYKY (23-kDa) subunit in the
Table 1
Relative steady-state levels of MRC proteins
Protein N2 LB25 LB26 LB27
NUO-1 1.00 0.29±0.05⁎ 0.75±0.07⁎ 0.45±0.04 ⁎
23-kDa 1.00 0.97±0.03 0.99±0.02 0.97±0.02
30-kDa 1.00 0.71±0.02⁎ 0.84±0.02⁎ 0.72±0.05 ⁎
COXI 1.00 0.58±0.03⁎ 0.86±0.04⁎ 0.66±0.03 ⁎
ATP-2 1.00 1.00±0.02 1.01±0.02 1.00±0.03
Reported values are normalized to levels in the wild type N2. Values are
means±S.D. of a minimum of three experiments.
⁎ Pb0.05 using two-sample t-test, compared to N2 wild type value.
117L.I. Grad, B.D. Lemire / Biochimica et Biophysica Acta 1757 (2006) 115–122mutants (Fig. 1, Table 1). The steady-state level of the mtDNA-
encoded COXI subunit of complex IV also showed a moderate
reduction. No differences were observed in the steady-state
levels of the complex V subunit ATP-2p. Thus, the nuo-1
mutations differentially affect the steady state levels of
individual complex I subunits and affect the levels of at least
one subunit in complex IV.
We investigated the effects of riboflavin supplementation on
the steady state levels of the complex I and complex IV subunits
in LB25 and LB27, the strains carrying the two most severe
alleles. LB26 was not investigated because the mutant
phenotype is mild and the effects of riboflavin supplementation
are not large. Mitochondria from the riboflavin-supplemented
strains showed significant increases in the relative abundance of
NUO-1 protein, increasing to 74% and 72% of wild type,
respectively (Fig. 1, Table 2). Surprisingly, COXI levels were
also elevated by riboflavin, increasing to 85% and 83% of wild
type, respectively (Fig. 1, Table 2). The steady-state levels of
the 30-kDa and 23-kDa complex I subunits and of the ATP-2p
subunit were not affected by riboflavin. Riboflavin differential-
ly affects the steady state levels of individual complex I
subunits. In addition, riboflavin modulates the levels of COXI, a
subunit of complex IV, an enzyme without a flavin cofactor.
3.2. nuo-1 mutations impair MRC complex assembly
To determine how the reduced steady state levels of MRC
subunits affect the amounts of fully assembled complexes, we
resolved mitochondrial proteins by blue native gel electropho-
resis (BN-PAGE). The gels were stained for NADH dehydro-
genase activity, an activity present in the complex I holoenzyme
and in some sub-complexes [38]. A species with high levels of
NADH dehydrogenase activity was detected in wild type
mitochondria migrating with an apparent molecular weight of
∼950-kDa; it most likely corresponds to complex I holoenzyme
(Fig. 2A). Much lower levels of NADH dehydrogenase activity
are associated with this 950-kDa species in mitochondria from
LB25, LB26 or LB27. In addition, LB25 and LB26 mitochon-Fig. 1. Steady-state levels of MRC proteins are diminished in mutant
mitochondria. 50 μg of isolated mitochondria from the wild type (N2) or the
nuo-1 mutants LB25–LB27 were loaded into each lane and specific subunits of
complexes I, IVand V were detected by Western blot analysis. Rb, mitochondria
were isolated from strains cultured in the presence of 1 μg/ml riboflavin.dria contain complexes with significant NADH dehydrogenase
activity migrating at ∼640-kDa and ∼600-kDa, respectively.
These smaller species are absent from wild type mitochondria.
LB27 mitochondria do not contain detectable NADH-dehydro-
genase activity in the 600–640 kDa range. In mitochondria from
riboflavin-supplemented LB25 and LB27, there is a significant
increase in the amount of NADH dehydrogenase activity at
∼640 kDa and of another species at ∼670 kDa (Fig. 2A).
However, riboflavin supplementation does not increase the
activity associated with the ∼950-kDa species.
To confirm that the high molecular weight NADH
dehydrogenase-active species are in fact related to complex I,
we used Western blot analysis with an antiserum directed
against the bovine 51-kDa subunit, which crossreacts with C.
elegans NUO-1. In wild type mitochondria, we detected a
strong but diffuse signal centered at ∼1-MDa, which corre-
sponds closely to the position of the ∼950-kDa NADH
dehydrogenase-active species (Fig. 2B). This confirms that
the C. elegans complex I is ∼950 kDa in size, similar to
mammalian complex I. Immunologically-detectable, high
molecular weight species containing NUO-1 are considerably
less abundant in LB26 and almost absent in LB25 and LB27.
This is in agreement with the steady-state levels of NUO-1
determined by Western blot analysis after denaturing gel
electrophoresis (Fig. 1). The diffuse NUO-1-specific signal in
LB26 mitochondria is shifted towards smaller molecular
weights, being centered at ∼800-kDa. This suggests that the
∼800-kDa signal either represents a complex I sub-complex or
that the holoenzyme is unstable during long electrophoresis
required for BN-PAGE. Mitochondria from riboflavin-supple-
mented LB25 and LB27 demonstrate significant increases in
NUO-1-specific signal. The NUO-1-specific signal in theseTable 2
Effects of riboflavin on protein steady-state levels
Protein LB25 LB25+Rb LB27 LB27+Rb
NUO-1 0.29±0.05 0.74±0.04⁎ 0.45±0.04 0.72±0.03⁎
23-kDa 0.97±0.03 0.98±0.02 0.97±0.02 0.99±0.01
30-kDa 0.71±0.02 0.73±0.01 0.72±0.05 0.76±0.04
COXI 0.58±0.03 0.85±0.04⁎ 0.66±0.03 0.83±0.04⁎
ATP-2 1.00±0.02 1.02±0.05 1.00±0.03 0.99±0.01
Reported values are normalized to levels in the wild typeN2. Values aremeans±S.D.
of a minimum of three experiments.
⁎ Pb0.05 using two-sample t-test, compared to the corresponding unsupple-
mented strain.
Fig. 3. Complex IV assembly is impaired in nuo-1 mutant mitochondria.
Mitochondrial proteins (300 μg) were resolved by BN-PAGE and the gel stained
for cytochrome c oxidase activity. Rb, mitochondria were isolated from strains
cultured in the presence of 1 μg/ml riboflavin; C IV(m), monomeric complex IV;
C IV(d), dimeric complex IV; ∼160 and ∼120 indicate the sizes of mutant-
specific assembly intermediates.
Fig. 2. Complex I assembly is impaired in nuo-1 mutant mitochondria. (A)
Mitochondrial proteins (300 μg in each lane) were resolved by BN-PAGE and
the gel stained for NADH dehydrogenase activity. (B) Mitochondrial proteins
(300 μg in each lane) were resolved by BN-PAGE and the gel was transferred for
Western blot analysis with polyclonal antiserum against the bovine 51-kDa
subunit of complex I. Rb, mitochondria were isolated from strains cultured in the
presence of 1 μg/ml riboflavin; C I, fully assembled complex I holoenzyme;
∼600 and ∼640 indicate the sizes of LB26 and LB25-specific assembly
intermediates, respectively.
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kDa (Fig. 2B). The signal by Western blot overlaps with the
position of the ∼640-kDa species seen by NADH dehydroge-
nase activity staining, strongly suggesting that this species is a
NUO-1-containing assembly intermediate of complex I. The
diffuseness of the signal also suggests that NUO-1 is not present
in a single discrete species or that this species is unstable under
the conditions of electrophoresis.
We also investigated the assembly of complex IV in the
nuo-1 mutants. Mitochondrial proteins were separated by BN-
PAGE and the gels stained for cytochrome c oxidase activity.
Wild type mitochondria contain five distinct cytochrome c
oxidase-active species (Fig. 3). A major species with an
apparent molecular weight of 210-kDa, likely representing
monomeric complex IV, appears first during the staining
reaction. Minor species of 130, 165, 270 and 420 kDa, thelatter likely representing dimeric complex IV, appear later
during the in-gel staining reaction. Mitochondria from the
LB25, LB26 and LB27 mutants all produce different staining
patterns. The 130-, 210- and 270-kDa species are present in
all three mutants, although their staining intensities are
variably reduced compared to wild type. Complex IV dimer
(420-kDa species) is only weakly detected in LB25 and LB27
mitochondria and appears absent in LB26. The 165-kDa
species is absent in all three mutants; instead, an alternate
species with an apparent molecular weight of ∼160-kDa is
present. Finally, a smaller additional species at ∼120-kDa is
present in the mutants but not in wild type.
We further examined the effects of riboflavin on the
assembly of complex IV because the mutant strains showed
riboflavin-responsive increases in the steady-state level of
COXI (Fig. 3). The most obvious riboflavin-dependent effect is
the disappearance of the 120-kDa species from the mutants,
making the cytochrome c oxidase staining patterns more closely
resemble that of wild type. However, the 160-kDa species
remains intact, as opposed to the 165-kDa species seen in the
wild type. The overall cytochrome c oxidase staining intensities
of the mutant mitochondria are consistently increased by
riboflavin, suggesting complex IV assembly and/or stability is
enhanced by the vitamin. Our analysis has revealed the presence
of aberrant cytochrome c oxidase complexes in nuo-1 mutants
and that the abundance of some of these is responsive to
riboflavin supplementation.
3.3. Riboflavin increases the activities of complexes I and IV
The in-gel activity staining suggests that riboflavin increases
the amounts of assembled, active complexes I and IV. However,
the in-gel assays are only semi-quantitative and require that the
complexes be stable during electrophoresis for detection. We
measured the rotenone-sensitive NADH-decylubiquinone
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reported previously, these are approximately 30% of the wild
type (Fig. 4A) [13]. Mitochondria isolated from riboflavin-
supplemented cultures contain more than twice the amount of
complex I activity (Fig. 4A). Likewise, the cyanide-sensitive
cytochrome c oxidase activities of LB25 and LB27 mitochon-
dria are ∼50% of wild type levels (Fig. 4B). The activities also
increase substantially when the strains are cultured in the
presence of riboflavin.
4. Discussion
We have modeled pathogenic human complex I mutations in
C. elegans in an effort to elucidate the biochemical and
bioenergetic mechanisms of MRC. Our previous study
suggested that mutations in complex I cause pathology in at
least three ways: (1) A reduced ability to oxidize NADH
perturbs the cellular redox balance and impairs other metabolic
pathways. (2) The rate of oxygen free-radical generation is
accelerated, leading to oxidative stress. (3) Impaired OXPHOS
results in an energy deficit. In this work, we have extended our
understanding of these complex I mutations by investigating
their effects on the assembly and activity of complexes I and IV.
In addition, we have revealed an unexpected effect of riboflavin
on the assembly of the cytochrome c oxidase complex.
A key result of our investigation is the clear demonstration of
reduced levels of complex I holoenzyme in nuo-1 mutants.
Similar observations have been reported for human complex I
mutations affecting a variety of nuclear or mtDNA-encoded
subunits [27,28,38–41]. Of the complex I subunits we
investigated, the NUO-1 protein itself showed the greatest
reduction in steady-state levels. The A352, T434 and A443
mutations we introduced into the nuo-1 gene affect conserved
residues. We believe these residues are important for protein
folding and that newly-synthesized mutant NUO-1 protein is
more susceptible to degradation and/or is inefficiently assem-
bled into holoenzyme. Similarly, when the equivalent T434Fig. 4. Riboflavin increases the enzyme activities of complexes I and IV in nuo-1 m
decylubiquinone oxidoreductase activity. (B) Complex IV was measured as the cyan
four independent trials. Black bars represent activities in mitochondria of strains grow
the presence of 1 μg/ml riboflavin. *Pb0.05 compared to corresponding unsupplemmutation was modeled in Neurospora crassa, the mutant
protein was less efficiently assembled than the wild type and
resulted in approximately half the wild type activity [42]. In
contrast to our results, the equivalent A352 mutant did not
assemble into complex I and the authors suggested that the
subunit was degraded [42]. In agreement with our conclusions,
the Neurospora data suggest that the decreased levels of
complex I activity in the membrane are mainly due to
diminished assembly or stability, rather than to reduced activity
of the mutated enzymes [42].
The A352, T434 and A443 residues are not located in known
cofactor-binding motifs but we do not have sufficiently high
resolution structural information to eliminate a role for them in
cofactor binding [7]. Recently, the organization of the iron-
sulfur centers of the Thermus thermophilus complex I was
determined by X-ray crystallography [43]. The authors
suggested that the FMN cofactor of the 51-kDa subunit may
be located between iron–sulfur centers N1a and N3, judging
from possible access channels for NADH [43].
Unlike bovine or human complex I, there is no information
on the localization of specific subunits in the C. elegans
complex I holoenzyme. There is, however, mounting evidence
that mammalian complex I is assembled from a series of
modules or sub-complexes [44]. Both the 30-kDa and the 23-
kDa subunits are located within the peripheral arm of complex I
and more specifically with the Iλ fraction, the same sub-
complex that contains the 51-kDa subunit [5,45]. The mutations
in C. elegans nuo-1 affect the steady-state level of the 30-kDa
subunit but not of the 23-kDa subunit. This suggests that the
stability or assembly of certain sub-complexes is compromised
in the mutants, leading to the loss of specific subunits. Very little
is known about the 30-kDa subunit, as it contains no redox
cofactors, while the 23-kDa subunit is believed to house two
iron–sulfur clusters [7]. Models for the assembly of mammalian
complex I have been proposed but these are incomplete or
insufficiently detailed to allow us to suggest why the levels of
30-kDa and 23-kDa subunits are differentially affected by theutants. (A) Complex I activity was measured as the rotenone-sensitive NADH-
ide-sensitive oxidation of reduced cytochrome c. Reported values are means of
n in the absence of riboflavin; white bars represent activities of strains cultured in
ented sample using a two-sample t-test.
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available antibodies against C. elegans complex I subunits,
more detailed investigations into the assembly and localization
of NUO-1 are currently severely restricted.
With respect to complex I subunits, the beneficial effects of
riboflavin are limited to the NUO-1 protein. This is perhaps not
surprising since it is the NUO-1 subunit itself that carries the
FMN cofactor and it is well known that ligands can promote
protein folding and stabilization. Supplementation with ribo-
flavin likely results in increased FMN availability, leading to
enhanced rates of NUO-1 folding to a more stable cofactor-
bound form and to assembly into stable sub-complexes. The
appearance of lower molecular weight assembly intermediates
and the continued low abundance of 30-kDa subunit in
riboflavin-supplemented mutant mitochondria indicate that
stabilizing and assembling mutant species of NUO-1 are not
sufficient to entirely correct the assembly defects. We did not
detect significant increases in the activity of the 950-kDa
species by BN-PAGE and histochemical analysis in the
riboflavin-treated mutants (Fig. 2A), yet we detected more
NUO-1 protein byWestern blotting in the 600–1,000 kDa range
(Fig. 2B). We suggest that the mutant complexes may not be
fully stable during the extended electrophoresis conditions
required for BN-PAGE. The diffuseness of the NUO-1 signal
detected by Western blotting after BN-PAGE suggests that
mutant NUO-1 protein can be assembled into a high molecular
weight species but that only a fraction of this species survives
BN-PAGE; most of the NUO-1 protein is found in faster
migrating species that are probably unstable and have little or no
activity. Our results emphasize the importance of studying the
assembly pathways of MRC enzymes for diagnosing and
treating mitochondrial disease.
We have identified aberrant assembly of complex IV as
contributing to the nuo-1 mutant phenotypes. Patients with
mutations in the NDUFS2 and NDUFS4 subunits of complex I
presented with a decreased level of complex III dimer [38].
These observations suggest that a physical interaction between
complexes I and III may exist. This is supported by genetic
evidence; a mutation in cytochrome b of complex III produces a
combined deficiency in complexes I and III [47]. A super-
complex comprising complexes I and III and up to four copies
of complex IV has been detected in mammalian mitochondria
[48]. In fact, almost all the complex I was found associated with
complex III. Our previous investigations did not identify a
consistent effect of the nuo-1 mutations on complex III activity
[13]. Under certain detergent conditions, a direct interaction
between complexes I and IV without complex III is detected
[48].
Combined deficiencies in complexes I and IV have been
reported but the precise molecular lesions are unknown [22,49–
51]. Complex IV deficiency has been presumed to be secondary
to complex I deficiency [51]. Complex I deficiency may
destabilize complex IV by preventing or diminishing the
formation of one or more of the supercomplexes seen in
mammalian mitochondria. Alternatively, complex I dysfunction
may indirectly affect assembly of complex IV through altered
expression of complex IV subunits, including isoforms, or ofcomplex IV assembly factors. These altered expression patterns
may account for the relatively small size differences in the
complex IV species seen by BN-PAGE and activity staining
(Fig. 3). Finally, complex I deficiency may result in a lower
membrane potential across the mitochondrial inner membrane,
which is necessary for complex IV assembly [52]. Riboflavin
may thus exert its beneficial effects on complex IV either
through enhancing complex I assembly and stability or
indirectly through enhancing complex I activity and energy
production.
In conclusion, we have shown that the catalytic deficiencies
of complexes I and IVobserved in C. elegans nuo-1mutants are
due to their impaired assembly or stability. NUO-I mutants have
reduced levels of fully assembled complex I and lower
molecular weight assembly intermediates. Riboflavin supple-
mentation stabilizes the steady-state levels of NUO-1, thereby
increasing the abundance of fully assembled complex I and of
specific assembly intermediates. NUO-1 mutants also demon-
strate aberrant complex IV assembly patterns, which are
partially corrected by riboflavin. We suggest that the effects
of riboflavin are profound because this vitamin improves the
activities of both complexes I and IV, which in turn leads to
reduced oxidative stress and lactic acidosis and increased
metabolic function.
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